
==== Front
ACS OmegaACS OmegaaoacsodfACS Omega2470-1343American Chemical Society 3145978910.1021/acsomega.9b00407ArticleCascade Reaction of 1,1-Enediamines with 2-Benzylidene-1H-indene-1,3(2H)-diones:
Selective Synthesis of Indenodihydropyridine and Indenopyridine Compounds Luo Qin †Huang Rong †Xiao Qiang Kong Ling-Bin Lin Jun *Yan Sheng-Jiao *Key Laboratory of Medicinal
Chemistry for Natural Resource, Ministry of Education, School of Chemical
Science and Technology, Yunnan University, Kunming 650091, P. R. China* E-mail: linjun@ynu.edu.cn. Tel/fax: +86 87165031633 (J.L.).* E-mail: yansj@ynu.edu.cn.
Tel/fax: +86 87165031633 (S.-J.Y.).11 04 2019 30 04 2019 4 4 6637 6646 12 02 2019 04 03 2019 Copyright © 2019 American Chemical Society2019American Chemical SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

A concise and environmentally
friendly route for the synthesis
of diverse indenodihydropyridines (3) via a cascade reaction
of 1,1-eneamines (1) with benzylidene-1H-indene-1,3(2H)-diones (BIDs) (2) in
ethanol media was developed. The targeted compounds were efficiently
obtained by only filtration without any further post-treatment. In
the one-step cascade reaction, C–C and C–N bonds were
constructed. In addition, when 1,4-dioxane was used as a solvent and
the mixture of 1,1-eneamines (1) was refluxed with benzylidene-1H-indene-1,3(2H)-diones (BIDs) (2) for about 12 h, indenopyridine compounds (4) were
produced. Two kinds of indenopyridine derivatives 3–4 resulted from alternative solvents and temperatures. The
reaction had the following features: mild temperature, atom economy,
high yields, and potential biological activity of the product.

document-id-old-9ao9b00407document-id-new-14ao-2019-00407hccc-price
==== Body
Introduction
Group-assisted
purification1,2 allows for the synthesis
of diverse compounds without using traditional purification technologies
such as column chromatography. The focus of this technology is the
search for eco-friendly reagents and reactions to reduce the waste
generated from silica and solvents, particularly toxic solvents. The
aim is the development of an environmentally friendly and efficient
method to construct C–C and C–N bonds for the synthesis
of N-containing heterocyclic compounds.3−5

Pyridine derivatives
are vital N-containing heterocyclic compounds
that are widely found in natural products and synthetic drugs.6−22 Consequently, more pyridine derivatives have been designed and synthesized.6−22 Among them, 1,4-dihydropyridines and pyridine compounds have interesting
biological activity. For example, 1,4-dihdropyridines have various
biological activities and are widely used as drugs including calcium
channel blockers (for example, nifedipine, nimodipine, mebudipine,
and felodipine, Figure 1),6−8 mineralocorticoid receptor antagonists,8 sirtuin activators and inhibitors,9 transforming
growth factor-β signaling inhibitors,10 CB2 receptor agonists,11 cardiodepressant
activators,12 and Alzheimer’s disease
medications.13,14 Similarly, the pyridines have
broad-spectrum biological activity such as anti-human immunodeficiency
virus,15 antitumor,16−18 anti-inflammatory,19 antifungal,20 antihistamine,21 antidepressant, antiarthritic, antidiabetic,
antiglaucoma,22 and antiprion.

Figure 1 Biological
activity of dihydropyridines.

The indenonucleolus is a core unit of various natural alkaloids
like onychnine and polyfothine (Figure 2).23,24 Combining the structure of pyridines
or 1,4-dihydropyridines with indenones in one molecule is especially
important for novel pharmaceutical molecules. Consequently, various
indenopyridines have been constructed;25−32 these compounds (Figure 2) are important pharmaceuticals and bioactive natural products.
They have wide-spectrum biological activities and are mainly used
as antitumor or antiproliferative drugs25−29 (Figure 2; TAS-103,25 6-aryl-indeno[1,2-c]quinolones,26 compounds A28 and B29). However,
the molecules of 1,4-dihydropyridines combined with indenones are
not extensively used. Therefore, the development of effective methods
for the rapid preparation of the indenodihydropyridine (IDDP) library
is urgent.

Figure 2 Biological activity of indenopyridine derivatives and the targeted
compounds 3–4.

1,1-Enediamines (EDAMs) are fascinating and versatile building
blocks that are widely used to synthesize various fused heterocyclic
compounds.33−50 We have used EDAMs as bisnucleophilic reagents to react with isatins
via a cascade reaction for the synthesis of indenopyridine derivatives33,34 (Scheme 1).33 Other researchers have used a diversity of enamines
as substrates for the synthesis of various indenopyridine derivatives
through cascade reactions.35−38 Based on the importance of indenopyridine derivatives,
we explored the cascade of EDAMs for synthesis of indenopyridine derivatives
including indenopyridines and IDDPs.

Scheme 1 Methods for the Construction
of Indenopyridine Derivatives
In this article, we describe a cascade strategy for the
convergent
synthesis of a kind of IDDPs (3) and a type of indenopyridines
(4) through alternative solvents and temperatures. We
realize that one protocol for synthesis of two kinds of heterocycles
kills two birds with one stone. The reaction is particularly attractive
due to the following features: eco-friendliness (EtOH as a solvent
and without column chromatography for compound 3; air
as an oxidant to obtain compound 4), mild temperature,
atom economy, high yields, and potential biological activity of the
product.

Results and Discussion
To obtain the indenopyridine
derivatives, we searched for the optimal
reaction conditions that were based on the model reaction of the reaction
of EDAM 1a with benzylidene-1H-indene-1,3(2H)-dione (BID) 2a. Solvents including acetone,
ethanol, and 1,4-dioxane (Table 1, entries 1–3) were screened. The results showed
that the reaction could proceed in ethanol at room temperature (r.t.)
without any promoters (Table 1, entry 2) and give the target compound 3a with
50% yield. With the same solvent (ethanol) and increased reflux temperature,
the reaction produced compound 3a with a good yield (91%)
(Table 1, entry 5).
Using 1,4-dioxane as a solvent and refluxing for about 12 h resulted
in the target compound 4a with 90% yield (Table 1, entry 6). Different bases
such as Cs2CO3, t-BuOK, and
Et3N, and acid promoter HOAc were added to the reaction
mixture. The results showed that the three bases could not promote
the yield of the cascade reaction. Among them, Cs2CO3 and t-BuOK made the reaction more complicated
due to their stronger alkalinities (Table 1, entries 7 and 8). The promoters Et3N and HOAc slightly decreased the yield of the reaction (Table 1, entry 5 vs 9 and
10). Different promoters including Cs2CO3, t-BuOK, and Et3N and HOAc were added to 1,4-dioxane
and refluxed for 12 h. The promoters Cs2CO3, t-BuOK, and Et3N also slightly decreased the
yield of the reaction (Table 1, entry 5 vs 11–13). When HOAc was used as a promoter,
the reaction produced the indenopyridine 4a with 60%
yield (Table 1, entry
14). Finally, the reaction time was screened and it was revealed that
the cascade reaction for synthesis of 3a in ethanol and
refluxing for about 6 h led to the best yield (Table 1, entry 5 vs 15). The results showed that
the optimal reaction for synthesis of IDDP 3a is the
mixture in an environmentally friendly solvent and refluxing for about
6 h without any promoter. The optimal reaction for production of the
indenopyridine 4a was 1,4-dioxane used as a solvent and
refluxing for 12 h without any promoter (Table 1, entry 6 vs 16).

Table 1 Optimization
of the Reaction Conditionsa
entry	solvent	catalyst	T (°C)	time (h)	3a/yield (%)b	4a/yield (%)b	
1	acetone	−	r.t.	12	−	−	
2	EtOH	−	r.t.	12	50	−	
3	1,4-dioxane	−	r.t.	12	−	−	
4	acetone	−	reflux	12	complex	complex	
5	EtOH	−	reflux	12	91	−	
6	1,4-dioxane	−	reflux	12	−	90	
7	EtOH	Cs2CO3	reflux	12	complex	complex	
8	EtOH	t-BuOK	reflux	12	complex	complex	
9	EtOH	Et3N	reflux	12	85	trace	
10	EtOH	HOAc	reflux	12	80	trace	
11	1,4-dioxane	Cs2CO3	reflux	12	complex	complex	
12	1,4-dioxane	t-BuOK	reflux	12	complex	complex	
13	1,4-dioxane	Et3N	reflux	12	88	trace	
14	1,4-dioxane	HOAc	reflux	12	trace	60	
15	EtOH	−	reflux	6	93	−	
16	1,4-dioxane	−	reflux	6	trace	82	
a Reaction conditions: EDAM 1a (1.1 mmol)
and BID 2a (1.0 mmol) were dissolved
in a solvent (20 mL).

b Isolated
yield based on BID 2a.

Based on the optimal reaction conditions, we further
investigated
the scope and generality of the cascade reaction of the EDAMs 1 with BIDs 2. Different substituted EDAMs 1 and other BIDs 2 were used in this protocol
(Table 2, entries 1–21).
The results revealed that the substituted group on EDAMs 1 has only a slight influence on the yield. Similarly, the substituted
groups of BIDs 2 also had slight effects on the yields
of the reaction. We concluded that different EDAMs 1 and
a variety of BIDs 2 are good substrates for this cascade
reaction and produce the target compounds 3a–u with excellent yields (90–98%).

Table 2 Synthesis of Indenodihydropyridines
(IDDPs) 3a
entry	R	R′	3	yield
(%)b	
1	p-FC6H4CH2	F	3a	93	
2	p-FC6H4CH2	Cl	3b	93	
3	p-FC6H4CH2	Me	3c	97	
4	p-ClC6H4CH2	Cl	3d	98	
5	p-ClC6H4	H	3e	97	
6	p-ClC6H4CH2	H	3f	96	
7	p-ClC6H4CH2	Me	3g	92	
8	p-ClC6H4	OMe	3h	94	
9	p-ClC6H4CH2CH2	OMe	3i	95	
10	C6H5CH2CH2	F	3j	93	
11	C6H5	Cl	3k	91	
12	C6H5CH2	Cl	3l	92	
13	C6H5CH2CH2	Cl	3m	92	
14	C6H5CH2CH2	H	3n	94	
15	C6H5CH2	Me	3o	96	
16	C6H5	OMe	3p	90	
17	C6H5CH2CH2	OMe	3q	95	
18	p-OMeC6H4CH2CH2	F	3r	93	
19	p-OMeC6H4CH2CH2	Cl	3s	93	
20	p-OMeC6H4CH2CH2	H	3t	90	
21	p-OMeC6H4CH2CH2	Me	3u	93	
a Reaction
conditions: EDAMs 1 (1.1 mmol), BIDs 2 (1.0
mmol), and EtOH (20
mL).

b Isolated yields based
on BIDs 2.

To obtain the indenopyridine compound library, we further explored
the universality of the cascade reaction for synthesis of compounds 4. A variety of EDAMs 1 and BIDs 2 were combined in this reaction under the optimal conditions (Table 3, entries 1–13). The results showed that the substituted EDAMs 1 had only a slight effect on the yields of compounds 4. In addition, the different substituents (H, F, Cl, Me, and OMe)
at the 4 and 4′ positions of BIDs 2 also had a
slight effect on the yield of compounds 4. In general,
the yield of the electron-withdrawing-group-substituted BIDs 2 was higher than that of the electron-donating-group-substituted
compound (Table 3,
entry 1 vs 7–8 vs 9). In summary, all of EDAMs 1 and BIDs 2 can be used as substrates to produce high
yields of the target compounds 4.

Table 3 Synthesis of Indenopyridine Compounds 4a
entry	R	R′	4	yield (%)b	
1	p-FC6H4CH2	F	4a	90	
2	p-FC6H4CH2	Me	4b	89	
3	p-ClC6H4CH2	F	4c	85	
4	p-ClC6H4CH2 CH2	H	4d	89	
5	p-ClC6H4CH2	Me	4e	84	
6	C6H5CH2	OMe	4f	89	
7	C6H5CH2CH2	F	4g	88	
8	C6H5CH2CH2	Cl	4h	88	
9	C6H5CH2CH2	OMe	4i	83	
10	p-OMeC6H4CH2CH2	F	4j	87	
11	p-OMeC6H4CH2CH2	H	4k	86	
12	p-OMeC6H4CH2CH2	Me	4l	89	
13	p-OMeC6H4CH2CH2	OMe	4m	82	
a Reaction
conditions: EDAMs 1 (1.1 mmol), BIDs 2 (1.0
mmol), and 1,4-dioxane
(20 mL).

b Isolated yields
based on BIDs 2.

Products 3–4 were characterized
by proton nuclear magnetic resonance (1H NMR), 13C nuclear magnetic resonance (13C NMR), Fourier transform
infrared (FTIR) spectroscopy, and high-resolution mass spectrometry
(HRMS). The results were all in agreement with the proposed structures.
To further testify the structure of the highly functionalized indenopyridine
derivatives, compound 4h was selected as the representative
compound and characterized by X-ray crystallography, as shown in Scheme 2 (CCDC 1885549) (ellipsoids
are drawn at the 30% probability level).

Scheme 2 Mechanism for the
Synthesis of Target Compounds 3–4
A proposed mechanism for this
cascade reaction is shown in Scheme 2. First, the α-C
of EDAMs 1 attacks the C=C bond of the BIDs 1 to generate the intermediates 5 via a Michael
reaction promoted by the base (EDAMs 1); high site-selectivity
of this step is vital. Second, the intermediates 5 form
the intermediates 6 via imine–enamine tautomerization.
Next, the intermediates 7 are obtained through the enol–keto
tautomerization of intermediate 6. Then, the intermediates 8 are produced by the intramolecular cyclization of the intermediates 7 where the amino group attacks the carbonyl of intermediates 7. Finally, the intermediate 8 loses one molecule
of water to produce the target compounds 3.

The
target compounds 3 can be easily oxidized by oxygen
of air at high temperature (by refluxing 1,4-dioxane). This oxidation
reaction can also proceed at room temperature for 1–2 weeks.
For example, when we cultivate the single crystal of compound 3m (for about 2 weeks), the only result is the structure of 4h rather than that of the compound 3m. We believe
that the target compounds 3 produce compounds 4 via oxidation reactions.

Conclusions
We report a concise
and environmentally friendly route for the
synthesis of diverse IDDPs (3) via a cascade reaction
of 1,1-eneamines (1) with benzylidene-1H-indene-1,3(2H)-diones (BIDs) (2) in
ethanol media without any promoters. The targeted compounds were efficiently
obtained by only filtration without any further post-treatment. Indenopyridine
compounds (4) were constructed by the cascade reaction
of EDAMs 1 with BIDs 2 in 1,4-dioxane and refluxing for 12 h without
any promoters. The result was two kinds of indenopyridine derivatives 3–4 through alternative solvents and temperatures.
The reaction had the following features: mild temperature, atom economy,
high yields, and potential biological activity of the product.

Experimental
Section
General Methods
All compounds were fully characterized
by spectroscopic data. The NMR spectra were recorded on a Bruker DRX500
or DRX600. Chemical shifts (δ) are expressed in parts per million, J values are given in hertz, and deuterated dimethyl sulfoxide
(DMSO)-d6 or CDCl3 was used
as a solvent. IR spectra were recorded on an FTIR Thermo Nicolet Avatar
360 using a KBr pellet. The reactions were monitored by thin-layer
chromatography (TLC) using silica gel GF254. The melting
points were determined on an XT-4A melting point apparatus and were
uncorrected. HRMS were performed on an Agilent LC/MSD TOF instrument.
X-ray diffraction was carried out by APEX DUO.

All chemicals
and solvents were used as received without further purification unless
otherwise stated. All chemicals were purchased from Adamas-β.
Column chromatography was performed on silica gel (Qingdao, 200–300
mesh). Compounds 1 were prepared according to the literature.50,51

General Procedure for the Synthesis of Compounds 3a–u
EDAMs 1 (1.1 mmol) were
dissolved in ethanol (20 mL), and then, BIDs 2 (1.0 mmol)
were added to the mixture. The mixture was stirred by refluxing for
about 6 h until full consumption of BIDs 2, which was
observed by thin-layer chromatography (TLC). The formed precipitate
was then filtered and washed with ethanol and a mixture of petroleum
ether and ethyl acetate (petro/AcOEt = 1/1) solution to produce the
pure products 3a–u. The products
were further identified by NMR spectroscopy, FTIR spectroscopy, and
HRMS.

2-((4-Fluorobenzyl)amino)-4-(4-fluorophenyl)-3-nitro-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3a)
Red solid; mp: 156.6–157.5 °C; IR (KBr): 3069,
1701, 1625, 1508, 1343, 1228 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ = 4.90–4.98
(m, 1H, ArH), 5.02–5.09 (m, 2H, CH2), 7.08 (t, J = 8.8 Hz, 2H, ArH), 7.26–7.30 (m, 5H, ArH), 7.31–7.38
(m, 1H, ArH), 7.47–7.55 (m, 3H, ArH), 7.81 (d, J = 7.5 Hz, 1H, ArH), 10.27 (s, 1H, NH), 11.55–11.62 (m, 1H,
NH); 13C NMR (125 MHz, DMSO-d6): δ = 37.5, 45.4, 110.8, 112.4, 115.2 (d, J = 20.0 Hz), 116.2 (d, J = 21.0 Hz), 121.1, 121.7,
129.8, 130.2, 130.8, 132.7, 132.8, 133.5, 139.8, 151.7, 152.1, 161.4
(d, J = 240.0 Hz), 162.2 (d, J =
242.5 Hz), 190.8. HRMS (TOF ES+): m/z calcd for C25H18F2N3O3 [M + H]+, 446.1311; found, 446.1309.

4-(4-Chlorophenyl)-2-((4-fluorobenzyl)amino)-3-nitro-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3b)
Red solid; mp: 222.6–223.5 °C; IR (KBr): 3442,
1689, 1631, 1511, 1342, 1070 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ = 4.82–5.01
(m, 3H, 1CH2, 1ArH), 7.17–7.38 (m, 8H, CH2), 7.47–7.55 (m, 3H, ArH), 7.78–7.87 (m, 1H, ArH),
10.28 (s, 1H, NH), 11.56–11.60 (m, 1H, NH); 13C
NMR (125 MHz, DMSO-d6): δ = 37.8,
45.4, 110.6, 112.0, 116.2 (d, J = 21.3 Hz), 121.1,
121.7, 128.5, 129.8, 130.1, 130.2, 130.3, 130.5, 130.9, 132.6, 132.9,
133.5, 142.6, 151.7, 152.2, 162.2 (d, J = 242.5 Hz),
190.7. HRMS (TOF ES+): m/z calcd for C25H18ClFN3O3 [M + H]+, 462.1015; found, 462.1014.

2-((4-Fluorobenzyl)amino)-3-nitro-4-(p-tolyl)-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3c)
Red solid; mp:
187.8–188.7 °C; IR (KBr): 3442,
1688, 1631, 1511, 1342, 1069 cm–1; 1H
NMR (600 MHz, DMSO-d6): δ = 2.22
(s, 3H, CH3), 4.92–5.06 (m, 3H, 1CH2,
1ArH), 7.05 (d, J = 7.9 Hz, 2H, ArH), 7.13 (d, J = 8.0 Hz, 2H, ArH), 7.26–7.29 (m, 3H, ArH), 7.30–7.37
(m, 1H, ArH), 7.46–7.54 (m, 3H, ArH), 7.78 (d, J = 7.3 Hz, 1H, ArH), 10.23 (s, 1H, NH), 11.54–11.59 (m, 1H,
NH); 13C NMR (150 MHz, DMSO-d6): δ = 21.0, 37.7, 45.3, 111.0, 112.9, 116.2 (d, J = 21.0 Hz), 120.9, 121.7, 127.8, 129.1, 130.2, 130.4, 130.7, 132.8,
133.6, 136.0, 136.4, 140.7, 151.7, 151.9, 162.2 (d, J = 241.5 Hz), 190.8. HRMS (TOF ES+): m/z calcd for C26H21FN3O3 [M + H]+, 442.1561; found, 442.1565.

2-((4-Chlorobenzyl)amino)-4-(4-chlorophenyl)-3-nitro-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3d)
Red solid; mp: 215.2–216.1 °C; IR (KBr): 3309,
1688, 1627, 1341, 1092, 1070 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ = 4.95–4.97
(m, 1H, ArH), 5.04–5.10 (m, 2H, CH2), 7.29–7.37
(m, 6H, ArH), 7.47–7.53 (m, 5H, ArH), 7.78–7.82 (m,
1H, ArH), 10.27 (s, 1H, NH), 11.59 (s, 1H, NH); 13C NMR
(125 MHz, DMSO-d6): δ = 37.8 45.3,
110.6, 121.1, 121.8, 121.8, 128.5, 129.3, 129.3, 129.8, 129.8, 129.9,
129.9, 130.9, 131.5, 132.9, 136.4, 142.6, 151.8, 152.2, 190.7. HRMS
(TOF ES+): m/z calcd
for C25H17Cl2N3O3 [M + H]+, 478.0720; found, 478.0718.

2-((4-Chlorophenyl)amino)-3-nitro-4-phenyl-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3e)
Red solid; mp: 251.4–252.3 °C; IR (KBr): 3059,
1698, 1616, 1520, 1351, 1329 cm–1; 1H
NMR (600 MHz, DMSO-d6): δ = 5.16
(s, 1H, ArH), 7.15–7.21 (m, 1H, ArH), 7.25–7.30 (m,
6H, ArH), 7.32–7.44 (m, 1H, ArH), 7.48–7.58 (m, 1H,
ArH), 7.59–7.64 (m, 2H, ArH), 7.72–7.80 (m, 2H, ArH),
10.73 (s, 1H, NH), 12.05 (s, 1H, NH); 13C NMR (150 MHz,
DMSO-d6): δ = 38.4, 112.5, 112.9,
121.1, 121.6, 125.0, 126.9, 127.1, 128.0, 128.3, 128.7, 128.9, 129.8,
130.7, 131.3, 132.7, 135.8, 136.4, 143.6, 190.8. HRMS (TOF ES+): m/z calcd for C24H17ClN3O3 [M + H]+, 430.0953;
found, 430.0955.

4-(4-Methoxyphenyl)-3-nitro-2-(phenethylamino)-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3f)
Red solid; mp: 220.7–221.6 °C; IR (KBr): 3443,
1699, 1633, 1510, 1324, 1071 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ = 3.03
(t, J = 7.0 Hz, 2H, CH2), 3.68 (s, 1H,
OCH3), 3.96–4,03 (m, 2H, NCH2), 4.93
(s, 1H, ArH), 6.78 (d, J = 8.5 Hz, 2H, ArH), 7.09
(d, J = 8.5 Hz, 2H, ArH), 7.20–7.29 (m, 2H,
ArH), 7.32–7.37 (m, 5H, ArH), 7.46–7.50 (m, 1H, ArH),
7.82 (d, J = 7.5 Hz, 1H, ArH), 9.98 (s, 1H, NH),
11.36–11.43 (m, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 35.3, 37.2, 44.1, 55.5, 110.7
112.7, 113.9, 121.1, 121.6, 127.1, 128.9, 129.0, 129.0, 129.4, 130.6,
132.7, 135.8, 136.5, 138.6, 151.7, 151.9, 158.3, 190.9. HRMS (TOF
ES+): m/z calcd for C27H24N3O4 [M + H]+, 454.1761; found, 454.1761.

2-((4-Chlorobenzyl)amino)-3-nitro-4-(p-tolyl)-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3g)
Red solid; mp:
206.5–207.4 °C; IR (KBr): 3438,
1701, 1631, 1520, 1331, 1320 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ = 2.22
(s, 3H, CH3), 4.91–4.99 (m, 1H, ArH), 5.00 (s, 1H,
CH2), 5.02–5.10 (m, 1H, CH2), 7.05 (d, J = 8.0 Hz, 2H, ArH), 7.12 (d, J = 7.5
Hz, 2H, ArH), 7.26–7.31 (m, 1H, ArH), 7.31–7.38 (m,
1H, ArH), 7.47–7.52 (m, 5H, ArH), 7.76 (d, J = 7.0 Hz, 1H, ArH), 10.22 (s, 1H, NH), 11.53–11.60 (m, 1H,
NH); 13C NMR (125 MHz, DMSO-d6): δ = 21.1, 37.7, 45.3, 111.0, 112.9, 120.9, 121.7, 127.8,
129.1, 129.3, 130.1, 130.7, 132.7, 132.8, 132.9, 136.0, 136.4, 136.5,
140.7, 151.8, 151.9, 190.8. HRMS (TOF ES+): m/z calcd for C26H21ClN3O3 [M + H]+, 458.1266; found, 458.1264.

2-((4-Chlorophenyl)amino)-4-(4-methoxyphenyl)-3-nitro-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3h)
Red solid; mp: 229.2–230.1 °C; IR (KBr): 3060,
1699, 1617, 1510, 1351, 1258 cm–1; 1H
NMR (600 MHz, DMSO-d6): δ = 3.70–3.77
(m, 3H, OCH3), 5.10 (s, 1H, ArH), 6.85 (d, J = 8.4 Hz, 2H, ArH), 7.22 (d, J = 8.4 Hz, 2H, ArH),
7.28–7.37 (m, 2H, ArH), 7.38–7.45 (m, 1H, ArH), 7.49–7.62
(m, 1H, ArH), 10.69 (s, 1H, NH), 12.02 (s, 1H, NH); 13C
NMR (150 MHz, DMSO-d6): δ = 37.4,
55.5, 112.8, 113.2, 114.1, 114.1, 121.0, 121.5, 126.8, 129.0, 129.0,
130.0, 130.6, 131.2, 132.7, 132.9, 135.7, 136.5, 149.3, 158.5, 190.9.
HRMS (TOF ES+): m/z calcd
for C25H19ClN3O4 [M +
H]+, 460.1059; found, 460.1061.

2-((4-Chlorophenethyl)amino)-4-(4-methoxyphenyl)-3-nitro-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3i)
Red solid; mp: 233.0–233.9 °C; IR (KBr): 3229,
1693, 1633, 1508, 1313, 1268 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ = 3.04
(t, J = 7.0 Hz, 2H, CH2), 3.68 (s, 3H,
OCH3), 3.96–4.03 (m, 2H, NCH2), 6.79
(d, J = 8.5 Hz, 2H, ArH), 7.09 (d, J = 8.5 Hz, 2H, ArH), 7.24–7.30 (m, 1H, ArH), 7.30–7.
37 (m, 1H, ArH), 7.38 (s, 4H, ArH), 7.44–7.51 (m, 1H, ArH),
7.81 (d, J = 7.5 Hz, 1H, ArH), 9.97 (s, 1H, NH),
11.36–11.42 (m, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 34.6, 37.1, 43.8, 55.5, 110.7,
112.7, 113.9, 121.1, 121.5, 128.7, 128.9, 130.6, 131.3, 131.8, 132.7,
132.8, 135.8, 136.5, 137.7, 151.8, 151.9, 158.3, 190.8. HRMS (TOF
ES+): m/z calcd for C27H23ClN3O4 [M + H]+, 488.1372; found, 488.1373.

4-(4-Fluorophenyl)-3-nitro-2-(phenethylamino)-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3j)
Red solid; mp: 209.2–210.1 °C; IR (KBr): 3436,
1697, 1632, 1505, 1356, 1068 cm–1; 1H
NMR (600 MHz, DMSO-d6): δ = 3.04
(t, J = 7.1 Hz, 2H, CH2), 3.97–4.03
(m, 2H, NCH2), 4.98 (s, 1H, ArH), 7.02–7.08 (m,
2H, ArH), 7.21–7.24 (m, 3H, ArH), 7.25–7.30 (m, 1H,
ArH), 7.32–7.37 (m, 5H, ArH), 7.45–7.51 (m, 1H, ArH),
7.84 (d, J = 7.2 Hz, 1H, ArH), 10.01 (s, 1H, NH),
11.39–11.43 (m, 1H, NH); 13C NMR (150 MHz, DMSO-d6): δ = 35.3, 37.5, 44.1, 110.3, 112.1,
115.2 (d, J = 21.0 Hz), 121.3, 121.6, 127.1, 129.0,
129.4, 129.7, 129.8, 130.7, 132.7, 136.4, 138.6, 139.9, 151.8, 152.2,
161.3 (d, J = 240.0 Hz), 190.8. HRMS (TOF ES+): m/z calcd for C26H21FN3O3 [M + H]+, 442.1561;
found, 442.1563.

4-(4-Methoxyphenyl)-3-nitro-2-(phenylamino)-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3k)
Red solid; mp: 226.5–227.4 °C; IR (KBr): 3048,
2928, 1698, 1657, 1619, 1512 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ = 3.70
(s, 3H, OCH3), 5.10 (s, 1H, ArH), 6.85 (d, J = 8.5 Hz, 2H, ArH), 7.22 (d, J = 8.5 Hz, 2H, ArH),
7.28–7.43 (m, 3H, ArH), 7.46–7.50 (m, 1H, ArH), 7.51–7.59
(m, 5H, ArH), 10.80 (s, 1H, NH), 12.18 (s, 1H, NH); 13C
NMR (125 MHz, DMSO-d6): δ = 37.4,
55.5, 112.8, 113.0, 114.1, 121.0, 121.5, 124.7, 127.0, 129.0, 130.2,
130.6, 132.7, 132.9, 135.7, 136.5, 136.6, 149.3, 152.2, 158.5, 190.9.
HRMS (TOF ES+): m/z calcd
for C25H20N3O4 [M + H]+, 426.1448; found, 426.1451.

2-(Benzylamino)-4-(4-chlorophenyl)-3-nitro-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3l)
Red solid; mp: 230.2–231.1 °C; IR (KBr): 3442,
1689, 1631, 1511, 1342, 1070 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ = 4.92–5.00
(m, 1H, ArH), 5.03–5.09 (m, 2H, CH2), 7.27–7.39
(m, 7H, ArH), 7.43–7.52 (m, 5H, ArH), 7.82 (d, J = 7.0 Hz, 1H, ArH), 10.31 (s, 1H, NH), 11.60–11.66 (m, 1H,
NH); 13C NMR (125 MHz, DMSO-d6): δ = 37.8, 46.1, 110.5, 112.0, 121.2, 121.7, 128.0, 128.4,
128.5, 128.8, 129.8, 130.9, 131.5, 132.6, 132.9, 136.3, 137.3, 142.6,
151.8, 152.3, 190.8. HRMS (TOF ES+): m/z calcd for C25H19ClN3O3 [M + H]+, 444.1109; found, 444.1114.

4-(4-Chlorophenyl)-3-nitro-2-(phenethylamino)-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3m)
Red solid; mp: 164.9–165.8 °C; IR (KBr): 3442,
1630, 1513, 1347, 1087, 1068 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ = 3.01–3.08
(m, 2H, CH2), 3.98–4.03 (m, 2H, NCH2),
4.97 (s, 1H, ArH), 7.21–7.38 (m, 12H, ArH), 7.44–7.51
(m, 1H, ArH), 7.85 (d, J = 7.0 Hz, 1H, ArH), 10.01
(s, 1H, NH), 11.42 (s, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 35.2, 37.8, 44.1, 110.1, 111.8,
121.3, 121.6, 127.1, 128.4, 129.0, 129.4, 129.4, 129.8, 130.8, 131.4,
132.7, 136.3, 138.6, 142.7, 151.8, 152.3, 190.7. HRMS (TOF ES+): m/z calcd for C26H21ClN3O3 [M + H]+, 458.1266;
found, 458.1268.

3-Nitro-2-(phenethylamino)-4-phenyl-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3n)
Red solid; mp: 223.5–224.4 °C; IR (KBr): 3442,
1702,
1630, 1519, 1314, 1070 cm–1; 1H NMR (500
MHz, DMSO-d6): δ = 3.02–3.08
(m, 2H, CH2), 3.98–4.03 (m, 2H, NCH2),
4.98 (s, 1H, ArH), 7.13–7.49 (m, 13H, ArH), 7.80–7.86
(m, 1H, ArH), 10.00 (s, 1H, NH), 11.40–11.45 (m, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ
= 35.3, 38.1, 44.1, 110.4 112.4, 121.2 121.6, 126.9, 127.1, 127.9,
128.5, 129.0, 129.4, 130.7, 132.7, 132.7, 136.4, 138.6, 143.7, 151.8,
152.2, 190.8. HRMS (TOF ES+): m/z calcd for C26H21N3O3 [M + H]+, 424.1656; found, 424.1656.

2-(Benzylamino)-3-nitro-4-(p-tolyl)-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3o)
Red solid; mp:
234.1–235.0 °C; IR (KBr): 3441,
1670, 1631, 1359, 1158, 1065 cm–1; 1H
NMR (600 MHz, DMSO-d6): δ = 2.22
(s, 3H, CH3), 4.98–5.05 (m, 3H, 1CH2,
1ArH), 7.05 (d, J = 7.9 Hz, 2H, ArH), 7.14 (d, J = 8.0 Hz, 2H, ArH), 7.21–7.26 (m, 1H, ArH), 7.27–7.30
(m, 1H, ArH), 7.32–7.36 (m, 2H, ArH), 7.42–7.48 (m,
4H, ArH), 7.79 (d, J = 7.2 Hz, 1H, ArH), 10.24 (s,
1H, NH), 11.58–11.65 (m, 1H, NH); 13C NMR (150 MHz,
DMSO-d6): δ = 21.0, 37.7, 46.1,
111.0 112.9, 120.9, 121.7, 127.8, 128.0, 128.2, 128.3, 129.1, 129.4,
130.7, 132.8, 136.0, 136.4, 137.3, 140.7, 151.8, 151.9, 190.8. HRMS
(TOF ES+): m/z calcd
for C26H22N3O3 [M + H]+, 424.1656; found, 424.1657.

4-(4-Methoxyphenyl)-3-nitro-2-(phenylamino)-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3p)
Red solid; mp: 226.5–227.4 °C; IR (KBr): 3048,
2928, 1698, 1657, 1619, 1512 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ = 3.70
(s, 3H, OCH3), 5.10 (s, 1H, ArH), 6.85 (d, J = 8.5 Hz, 2H, ArH), 7.22 (d, J = 8.5 Hz, 2H, ArH),
7.28–7.43 (m, 3H, ArH), 7.46–7.50 (m, 1H, ArH), 7.51–7.59
(m, 5H, ArH), 10.80 (s, 1H, NH), 12.18 (s, 1H, NH); 13C
NMR (125 MHz, DMSO-d6): δ = 37.4,
55.5, 112.8, 113.0, 114.1, 121.0, 121.5, 124.7, 127.0, 129.0, 130.2,
130.6, 132.7, 132.9, 135.7, 136.5, 136.6, 149.3, 152.2, 158.5, 190.9.
HRMS (TOF ES+): m/z calcd
for C25H20N3O4 [M + H]+, 426.1448; found, 426.1451.

4-(4-Methoxyphenyl)-3-nitro-2-(phenethylamino)-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3q)
Red solid; mp: 220.7–221.6 °C; IR (KBr): 3443,
1699, 1633, 1510, 1324, 1071 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ = 3.03
(t, J = 7.0 Hz, 2H, CH2), 3.68 (s, 1H,
OCH3), 3.96–4,03 (m, 2H, NCH2), 4.93
(s, 1H, ArH), 6.78 (d, J = 8.5 Hz, 2H, ArH), 7.09
(d, J = 8.5 Hz, 2H, ArH), 7.20–7.29 (m, 2H,
ArH), 7.32–7.37 (m, 5H, ArH), 7.46–7.50 (m, 1H, ArH),
7.82 (d, J = 7.5 Hz, 1H, ArH), 9.98 (s, 1H, NH),
11.36–11.43 (m, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 35.3, 37.2, 44.1, 55.5, 110.7
112.7, 113.9, 121.1, 121.6, 127.1, 128.9, 129.0, 129.0, 129.4, 130.6,
132.7, 135.8, 136.5, 138.6, 151.7, 151.9, 158.3, 190.9. HRMS (TOF
ES+): m/z calcd for C27H24N3O4 [M + H]+, 454.1761; found, 454.1761.

4-(4-Fluorophenyl)-2-((4-methoxyphenethyl)amino)-3-nitro-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3r)
Red solid; mp: 173.7–174.6 °C; IR (KBr): 3453,
1630, 1512, 1353, 1247, 1070 cm–1; 1H
NMR (600 MHz, DMSO-d6): δ = 2.93–2.99
(m, 2H, CH2), 3.66 (s, 3H, OCH3), 3.93–4.01
(m, 2H, NCH2), 4.98 (s, 1H, ArH), 6.86–6.89 (m,
2H, ArH), 7.03–7.06 (m, 2H, ArH), 7.21–7.28 (m, 5H,
ArH), 7.30–7.37 (m, 1H, ArH), 7.45–7.50 (m, 1H, ArH),
7.82 (d, J = 7.3 Hz, 1H, ArH), 9.98 (s, 1H, NH),
11.35–11.41 (m, 1H, NH); 13C NMR (150 MHz, DMSO-d6): δ = 34.5, 37.5, 44.3, 55.4, 110.3,
112.1, 114.5, 115.2 (d, J = 21.0 Hz), 121.3, 121.6,
129.7, 129.7, 130.4, 130.4, 130.7, 132.7, 136.4, 139.9, 151.8, 152.2,
158.5, 161.3 (d, J = 240.0 Hz), 190.8. HRMS (TOF
ES+): m/z calcd for C27H23FN3O4 [M + H]+, 472.1667; found, 472.1667.

4-(4-Chlorophenyl)-2-((4-methoxyphenethyl)amino)-3-nitro-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3s)
Red solid; mp: 213.2–214.1 °C; IR (KBr): 3394,
1702, 1656, 1616, 1593, 1339 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ = 2.96
(t, J = 7.0 Hz, 2H, CH2), 3.66 (s, 1H,
OCH3), 3.94–4.01 (m, 2H, NCH2), 4.97
(s, 1H, ArH), 6.88 (d, J = 8.5 Hz, 2H, ArH), 7.21
(d, J = 8.5 Hz, 2H, ArH), 7.23–7.31 (m, 5H,
ArH), 7.32–7.39 (m, 1H, ArH), 7.46–7.53 (m, 1H, ArH),
7.84 (d, J = 7.5 Hz, 1H, ArH), 10.00 (s, 1H, NH),
11.36–11.42 (m, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 34.5, 37.7, 44.4, 55.4, 110.1,
111.7, 114.4, 121.4, 121.6, 128.4, 129.8, 130.4, 130.5, 130.5, 130.8,
131.4, 132.7, 136.3, 142.7, 151.8, 152.4, 158.5, 190.8. HRMS (TOF
ES+): m/z calcd for C27H23ClN3O4 [M + H]+, 488.1372; found, 488.1371.

2-((4-Methoxyphenethyl)amino)-3-nitro-4-phenyl-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3t)
Red solid; mp: 164.0–164.9 °C; IR (KBr): 3062,
1702, 1625, 1492, 1349,1267 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ = 2.94–3.00
(m, 2H, CH2), 3.67 (s, 3H, OCH3), 3.94–4.01
(m, 2H, NCH2), 4.99 (s, 1H, ArH), 6.88 (d, J = 8.5 Hz, 2H, ArH), 7.11–7.18 (m, 1H, ArH), 7.19–7.28
(m, 7H, ArH), 7.31–7.38 (m, 1H, ArH), 7.45–7.52 (m,
1H, ArH), 7.82 (d, J = 7.0 Hz, 1H, ArH), 9.98 (s,
1H, NH), 11.37–11.43 (m, 1H, NH); 13C NMR (125 MHz,
DMSO-d6): δ = 34.5, 38.1, 44.3,
55.4, 110.4, 112.3, 114.4, 121.2, 121.6, 126.9, 127.9, 128.5, 130.4,
130.4, 130.7, 132.7, 136.4, 143.7, 151.9, 152.2, 158.5, 190.8. HRMS
(TOF ES+): m/z calcd
for C27H24N3O4 [M + H]+, 454.1761; found, 454.1758.

2-((4-Methoxyphenethyl)amino)-3-nitro-4-(p-tolyl)-1,4-dihydro-9H-indeno[2,1-b]pyridin-9-one (3u)
Red solid; mp:
217.2–218.1 °C; IR (KBr): 3455,
1640, 1512, 1342, 1247, 1070 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ = 2.19–2.29
(m, 3H, CH3), 2.93–2.99 (m, 2H, CH2),
3.64–3.73 (m, 3H, OCH3), 3.93–3.99 (m, 2H,
NCH2), 4.94 (s, 1H, ArH), 6.84–6.92 (m, 2H, ArH),
6.99–7.08 (m, 4H, ArH), 7.25–7.34 (m, 4H, ArH), 7.43–7.50
(m, 1H, ArH), 7.80 (d, J = 7.5 Hz, 1H, ArH), 9.93
(s, 1H, NH), 11.39 (d, J = 5.5 Hz, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ
= 21.0, 34.5, 37.6, 44.3, 55.4, 110.5, 112.5, 114.4, 121.1, 121.5,
127.8, 129.1, 130.4, 132.6, 132.6, 132.6, 132.8, 135.9, 136.4, 140.8,
151.8, 152.0, 158.5, 190.8. HRMS (TOF ES+): m/z calcd for C28H26N3O4 [M + H]+, 468.1918; found, 468.1919.

General Procedure for the Synthesis of Compounds 4a–m
EDAMs 1 (1.1 mmol) were
dissolved in 1,4-dioxane (20 mL), and then, BIDs 2 (1.0
mmol) were added to the mixture. The mixture was stirred by refluxing
for about 12 h until full consumption of BIDs 2, which
was observed by thin-layer chromatography (TLC). The reaction solution
was poured into 30 mL of water and extracted with an appropriate amount
of ethyl acetate. The combined organic phases were dried with anhydrous
Na2SO4 and then separated by column chromatography
(petro/AcOEt = 30/1) to obtain pure target products 4a–m with 82–90% yield. The products were
further identified by NMR spectroscopy, FTIR spectroscopy, and HRMS.

2-((4-Fluorobenzyl)amino)-4-(4-fluorophenyl)-3-nitro-9H-indeno[2,1-b]pyridin-9-one (4a)
Yellow solid; mp: 193.3–194.2 °C; IR (KBr):
3409, 1713, 1571, 1508, 1267, 1222 cm–1; 1H NMR (600 MHz, DMSO-d6): δ = 4.78–4.83
(m, 2H, CH2), 7.18 (t, J = 7.4 Hz, 2H,
ArH), 7.24–7.31 (m, 2H, ArH), 7.38–7.41 (m, 2H, ArH),
7.53–7.59 (m, 4H, ArH), 7.69–7.73 (m, 1H, ArH), 7.81–7.86
(m, 1H, ArH), 8.86–8.92 (m, 1H, NH); 13C NMR (150
MHz, DMSO-d6): δ = 44.5, 113.9,
115.5 (d, J = 21.0 Hz), 115.5 (d, J = 21.0 Hz), 121.6, 123.4, 128.0, 130.5, 130.6, 130.8, 132.9, 135.2,
135.7, 137.2, 140.5, 143.1, 153.6, 161.8 (d, J =
241.5 Hz), 163.0 (d, J = 243.0 Hz), 167.3, 188.1.
HRMS (TOF ES+): m/z calcd
for C25H16F2N3O3 [M + H]+, 444.1154; found, 444.1158.

2-((4-Fluorobenzyl)amino)-3-nitro-4-(p-tolyl)-9H-indeno[2,1-b]pyridin-9-one (4b)
Yellow solid; mp: 203.4–204.3
°C; IR (KBr):
3444, 2924, 1707, 1587, 1522, 1273 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 2.38
(s, 3H, CH3), 4.79 (d, J = 6.0 Hz, 2H,
CH2), 7.16–7.25 (m, 6H, ArH), 7.52–7.57 (m,
4H, ArH), 7.67–7.70 (m, 1H, ArH), 7.82 (d, J = 7.5 Hz, 1H, ArH), 8.76–8.79 (m, 1H, 1NH); 13C NMR (125 MHz, DMSO-d6): δ = 21.4,
44.5, 113.7, 115.5 (d, J = 21.3 Hz), 121.5, 123.3,
128.2, 128.5, 129.1, 130.5, 131.2, 132.7, 135.1, 135.8, 137.1, 139.1,
140.5, 143.8, 153.4, 161.8 (d, J = 241.3 Hz), 167.22,
188.1. HRMS (TOF ES+): m/z calcd for C26H19FN3O3 [M + H]+, 440.1405; found, 440.1406.

2-((4-Chlorobenzyl)amino)-4-(4-fluorophenyl)-3-nitro-9H-indeno[2,1-b]pyridin-9-one (4c)
Yellow solid; mp: 191.6–192.5 °C; IR (KBr):
3402, 1710, 1571, 1531, 1520, 1269 cm–1; 1H NMR (500 MHz, DMSO-d6): δ = 4.81
(d, J = 5.5 Hz, 2H, CH2), 7.26–7.30
(m, 2H, ArH), 7.38–7.42 (m, 4H, ArH), 7.51–7.59 (m,
4H, ArH), 7.68–7.72 (m, 1H, ArH), 7.81 (d, J = 7.0 Hz, 1H, ArH), 8.90–8.92 (m, 1H, NH); 13C
NMR (125 MHz, DMSO-d6): δ = 44.6,
114.0, 115.5 (d, J = 21.3 Hz), 121.6, 123.4, 128.0,
128.7, 130.3, 130.6, 130.8, 132.1, 134.2, 132.9, 135.2, 137.1, 138.6,
140.4, 143.1, 153.6, 163.0 (d, J = 243.8 Hz), 167.3,
188.1. HRMS (TOF ES+): m/z calcd for C25H16ClFN3O3 [M + H]+, 460.0859; found, 460.0861.

2-((4-Chlorophenethyl)amino)-3-nitro-4-phenyl-9H-indeno[2,1-b]pyridin-9-one (4d)
Yellow solid; mp: 253.0–253.9 °C; IR (KBr):
3379, 1705,
1611, 1589, 1522, 1276 cm–1; 1H NMR (500
MHz, DMSO-d6 + CDCl3): δ
= 2.98–3.01 (m, 2H, CH2), 3.86–3.90 (m, 2H,
NCH2), 7.30–7.32 (m, 6H, ArH), 7.43–7.45
(m, 3H, ArH), 7.54–7.56 (m, 2H, ArH), 7.67–7.70 (m,
1H, NH), 7.82 (d, J = 7.0 Hz, 1H, ArH), 8.27–8.29
(m, 1H, ArH); 13C NMR (125 MHz, DMSO-d6 + CDCl3): δ = 34.8, 43.3, 113.4, 121.4,
123.1, 128.0, 128.3, 128.7, 129.2, 130.7, 130.9, 131.5, 131.9, 132.5,
134.8, 137.2, 138.5, 140.6, 144.0, 153.9, 167.5, 188.0. HRMS (TOF
ES+): m/z calcd for C26H19ClN3O3 [M + H]+, 456.1109; found, 456.1106.

2-((4-Chlorobenzyl)amino)-3-nitro-4-(p-tolyl)-9H-indeno[2,1-b]pyridin-9-one (4e)
Yellow solid; mp: 202.9–203.8
°C; IR (KBr):
3414, 1708, 1617, 1589, 1271, 624 cm–1; 1H NMR (600 MHz, DMSO-d6): δ = 2.38,
(s, 3H, CH3),4.79 (d, J = 5.2 Hz, 2H,
CH2), 7.20–7.25 (m, 4H, ArH), 7.41 (d, J = 8.2 Hz, 2H, ArH), 7.50–7.57 (m, 4H, ArH), 7.67–7.69
(m, 1H, ArH), 7.79 (d, J = 7.4 Hz, 1H, ArH), 8.77–8.79
(m, 1H, NH); 13C NMR (150 MHz, DMSO-d6): δ = 21.4, 44.6, 113.8, 121.5, 123.3, 128.2, 128.5,
128.7, 129.1, 130.3, 131.3, 132.0, 132.7, 135.1, 137.0, 138.7, 139.1,
140.5, 143.9, 153.4, 167.2, 188.1. HRMS (TOF ES+): m/z calcd for C26H19ClN3O3 [M + H]+, 456.1109; found,
456.1114.

2-(Benzylamino)-4-(4-methoxyphenyl)-3-nitro-9H-indeno[2,1-b]pyridin-9-one (4f)
Yellow solid; mp: 227.2–228.1 °C; IR (KBr):
3408, 1706,
1584, 1521, 1507, 1276 cm–1; 1H NMR (600
MHz, DMSO-d6): δ = 3.83 (s, 3H,
OCH2), 4.79–4.84 (m, 2H, CH2), 6.96–7.02
(m, 2H, ArH), 7.21–7.30 (m, 3H, ArH), 7.32–7.38 (m,
2H, ArH), 7.46–7.51 (m, 2H, ArH), 7.50–7.57 (m, 2H,
ArH), 7.63–7.69 (m, 1H, ArH), 7.74–7.79 (m, 1H, ArH),
8.71–8.76 (m, 1H, NH); 13C NMR (150 MHz, DMSO-d6): δ = 45.1, 55.7, 113.6, 114.0, 121.4,
123.2, 123.3, 127.4, 128.4, 128.8, 129.9, 131.3, 132.6, 135.0, 137.1,
139.7, 140.5, 143.5, 153.4, 160.5, 167.2, 188.2. HRMS (TOF ES+): m/z calcd for C26H20N3O4 [M + H]+, 438.1448;
found, 438.1452.

4-(4-Fluorophenyl)-3-nitro-2-(phenethylamino)-9H-indeno[2,1-b]pyridin-9-one (4g)
Yellow solid; mp: 208.7–209.6 °C; IR (KBr):
3364, 1714,
1608, 1536, 1502, 1271 cm–1; 1H NMR (600
MHz, DMSO-d6): δ = 2.98 (t, J = 7.6 Hz, 2H, CH2), 3.85–3.88 (m, 2H,
NCH2), 7.22–7.24 (m, 1H, ArH), 7.26–7.29
(m, 2H, ArH), 7.33–7.34 (m, 4H, ArH), 7.35–7.39 (m,
3H, ArH), 7.53–7.58 (m, 2H, ArH), 7.69–7.72 (m, 1H,
ArH), 7.82 (d, J = 7.3 Hz, 1H, ArH), 8.40–8.42
(m, 1H, 1NH); 13C NMR (150 MHz, DMSO-d6): δ = 35.4, 43.6, 113.5, 115.5 (d, J = 21.0 Hz), 121.5, 123.3, 126.7, 128.2, 128.9, 129.2, 130.5, 130.5,
132.8, 135.1, 137.2, 139.6, 140.5, 143.3, 153.9, 162.9 (d, J = 244.5 Hz), 167.5, 188.0. HRMS (TOF ES+): m/z calcd for C26H19FN3O3 [M + H]+, 440.1405; found,
440.1407.

4-(4-Chlorophenyl)-3-nitro-2-(phenethylamino)-9H-indeno[2,1-b]pyridin-9-one (4h)
Yellow solid; mp: 206.2–207.1 °C; IR (KBr):
3414, 1712,
1575, 1521, 1270, 77 cm–1; 1H NMR (500
MHz, DMSO-d6): δ = 2.97–3.00
(m, 2H, CH2), 3.86–3.90 (m, 2H, CH2),
7.21–7.24 (m, 1H, ArH), 7.33–7.36 (m, 6H, ArH), 7.50–7.60
(m, 4H, ArH), 7.73 (t, J = 6.8 Hz, 1H, ArH), 7.85
(d, J = 7.5 Hz, 1H, ArH), 8.47–8.49 (m, 1H,
1NH); 13C NMR (125 MHz, DMSO-d6): δ = 35.4, 43.7, 113.5, 121.6, 123.4, 126.7, 128.6, 128.9,
129.3, 130.1, 131.0, 132.9, 134.2, 135.2, 137.3, 139.6, 140.5, 143.2,
154.1, 167.5, 188.0. HRMS (TOF ES+): m/z calcd for C26H19ClN3O3 [M + H]+, 456.1109; found, 456.1111.

4-(4-Methoxyphenyl)-3-nitro-2-(phenethylamino)-9H-indeno[2,1-b]pyridin-9-one (4i)
Yellow solid; mp: 182.7–183.6 °C; IR (KBr): 3393, 1707,
1582, 1508, 1257, 1178 cm–1; 1H NMR (500
MHz, DMSO-d6): δ = 2.97 (t, J = 7.5 Hz, 2H, CH2), 3.83–3.87 (m, 5H,
NCH2, OCH3), 6.99 (d, J = 8.5
Hz, 2H, ArH), 7.21–7.27 (m, 3H, ArH), 7.32–7.35 (m,
4H, ArH), 7.53–7.57 (m, 2H, ArH), 7.68–7.71 (m, 1H,
ArH), 7.81 (d, J = 7.0 Hz, 1H, ArH), 8.23–8.25
(m, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ = 35.4, 43.6, 55.7, 113.3, 114.0, 121.4, 123.2,
123.5, 126.7, 128.9, 129.2, 129.9, 131.1, 132.6, 135.0, 137.2, 139.7,
140.6, 143.7, 153.7, 160.4, 167.4, 188.2. HRMS (TOF ES+): m/z calcd for C27H22N3O4 [M + H]+, 452.1605;
found, 452.1607.

4-(4-Fluorophenyl)-2-((4-methoxyphenethyl)amino)-3-nitro-9H-indeno[2,1-b]pyridin-9-one (4j)
Yellow solid; mp: 229.1–231.0 °C; IR (KBr):
3369, 2941, 1716, 1581, 1536, 1272 cm–1; 1H NMR (500 MHz, DMSO-d6 + CDCl3): δ = 2.92–2.95 (m, 2H, CH2), 3.32 (s, 1H,
OCH3), 3.86–3.87 (m, 2H, CH2), 6.85–6.87
(m, 2H, ArH), 7.20–7.24 (m, 4H, ArH), 7.32–7.36 (m,
2H, ArH), 7.52–7.57 (m, 2H, ArH), 7.68–7.72 (m, 1H,
ArH), 7.82–7.86 (m, 2H, ArH), 8.30–8.34 (m, 1H, NH); 13C NMR (125 MHz, DMSO-d6 + CDCl3): δ = 34.6, 43.8, 55.3, 113.5, 114.2, 115.3 (d, J = 21.3 Hz), 121.5, 123.1, 128.2, 130.1, 130.2, 131.3,
132.5, 134.8, 137.3, 140.6, 143.3, 154.1, 158.2, 162.9 (d, J = 245.0 Hz), 167.5, 188.0. HRMS (TOF ES+): m/z calcd for C27H21FN3O4 [M + H]+, 470.1511; found,
470.1513.

2-((4-Methoxyphenethyl)amino)-3-nitro-4-phenyl-9H-indeno[2,1-b]pyridin-9-one (4k)
Yellow solid; mp: 185.0–186.0 °C; IR (KBr):
3415, 1716,
1637, 1617, 1582, 1272 cm–1; 1H NMR (600
MHz, DMSO-d6): δ = 2.91 (t, J = 7.5 Hz, 2H, CH2), δ = 3.70 (s, 3H,
OCH3), 3.80–3.83 (m, 2H, CH2), 6.88 (d, J = 8.5 Hz, 2H, ArH), 7.23 (d, J = 8.5
Hz, 2H, ArH), 7.30–7.31 (m, 2H, ArH), 7.42–7.47 (m,
3H, ArH), 7.52–7.57 (m, 2H, ArH); 7.68–7.70 (m, 1H,
ArH), 7.80 (d, J = 7.4 Hz, 1H, ArH), 8.30–8.32
(m, 1H, NH); 13C NMR (150 MHz, DMSO-d6): δ = 34.6, 43.8, 55.5, 113.3, 114.4, 121.5, 123.2,
128.1, 128.4, 129.4, 130.2, 130.6, 131.5, 131.9, 132.7, 135.0, 137.2,
140.5, 144.0, 153.9, 158.3, 167.4, 188.0. HRMS (TOF ES+): m/z calcd for C27H22N3O4 [M + H]+, 452.1605;
found, 452.1605.

2-((4-Methoxyphenethyl)amino)-3-nitro-4-(p-tolyl)-9H-indeno[2,1-b]pyridin-9-one (4l)
Yellow solid; mp: 200.2–201.0
°C; IR (KBr):
3418, 2933, 1715, 1580, 1509, 1272 cm–1; 1H NMR (500 MHz, DMSO-d6 + CDCl3): δ = 2.40 (s, 3H, CH3), 2.92 (t, J = 7.3 Hz, 2H, CH2), 3.72 (s, 3H, OCH3), 3.83–3.86
(m, 2H, NCH2), 6.86 (d, J = 8.0 Hz, 2H,
ArH), 7.18–7.24 (m, 6H, ArH), 7.52–7.53 (m, 2H, ArH),
7.66–7.68 (m, 1H, ArH), 7.82 (d, J = 7.0 Hz,
1H, ArH), 8.18 (m, 1H, NH); 13C NMR (125 MHz, DMSO-d6 + CDCl3): δ = 21.4, 34.6,
43.8, 55.3, 113.3, 114.2, 121.3, 123.0, 128.0, 128.9, 128.9, 130.1,
130.8, 131.4, 132.3, 134.7, 137.3, 138.8, 140.7, 144.1, 153.9, 158.2,
167.5, 188.0. HRMS (TOF ES+): m/z calcd for C28H24N3O4 [M + H]+, 466.1761; found, 466.1761.

2-((4-Methoxyphenethyl)amino)-4-(4-methoxyphenyl)-3-nitro-9H-indeno[2,1-b]pyridin-9-one (4m)
Yellow solid; mp: 217.5–218.4 °C; IR (KBr):
3418, 1709, 1586, 1510, 1467, 1247 cm–1; 1H NMR (500 MHz, DMSO-d6 + CDCl3): δ = 2.87–2.94 (m, 2H, CH2), 3.71 (s, 3H,
OCH3), 3.78–3.85 (m, 5H, 1CH2, 1OCH3), 6.89 (d, J = 8.5 Hz, 2H, ArH), 7.00 (d, J = 8.7 Hz, 2H, ArH), 7.21–7.29 (m, 4H, ArH), 7.55–7.60
(m, 2H, ArH), 7.71–7.74 (m, 1H, NH), 7.81–7.86 (m, 1H,
ArH), 8.18–8.24 (m, 1H, ArH); 13C NMR (125 MHz,
DMSO-d6 + CDCl3): δ =
34.7, 43.8, 55.3, 55.5, 113.3, 113.8, 114.2, 121.3, 123.0, 123.6,
129.7, 130.1, 130.9, 131.4, 132.3, 134.6, 137.3, 140.7, 143.9, 153.9,
158.2, 160.4, 167.5, 188.1. HRMS (TOF ES+): m/z calcd for C28H24N3O5 [M + H]+, 482.1710; found, 482.1710.

Supporting Information Available
The
Supporting Information
is available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.9b00407.Spectroscopic
and analytical data as well as the original
copy of 1H and 13C NMR spectra of all new compounds
(PDF)

X-ray
crystallographic data (CIF file) of compound 4h (CCDC
1885549) (CIF)



Supplementary Material
ao9b00407_si_001.pdf

 ao9b00407_si_002.cif

 Author Contributions
† Q.L. and
R.H. contributed equally to this paper.

The authors declare no
competing financial interest.

Acknowledgments
This work was supported by the National Natural Science
Foundation
of China (Nos. 21662042, 81760621, 21362042, and U1202221), the Program
for Changjiang Scholars and Innovative Research Team in University
(IRT17R94), and the Natural Science Foundation of Yunnan Province
(2017FA003).
==== Refs
References
An G. ; Seifert C. ; Li G. 
N-Phosphonyl/phosphinyl
imines and group-assisted purification (GAP) chemistry/technology . Org. Biomol. Chem. 
2015 , 13 , 1600 –1617 . 10.1039/c4ob02254h .25523061 
Yu F.-C. ; Chen Z.-Q. ; Hao X.-P. ; Yan S.-J. ; Huang R. ; Lin J. 
Regioselective synthesis
of 9,10-dihydro-6H-chromeno[4,3-d]imidazo-[1,2-a]pyridin-6-one derivatives . RSC Adv. 
2014 , 4 , 6110 –6115 . 10.1039/c3ra46428h .
Jiang Y. ; Xu K. ; Zeng C. 
Use of Electrochemistry
in the Synthesis of Heterocyclic
Structures . Chem. Rev. 
2018 , 118 , 4485 –4540 . 10.1021/acs.chemrev.7b00271 .29039924 
Song Q.-W. ; Zhou Z.-H. ; He L.-N. 
Efficient, selective
and sustainable
catalysis of carbon dioxide . Green Chem. 
2017 , 19 , 3707 –3728 . 10.1039/C7GC00199A .
Biemolt J. ; Ruijter E. 
Advances in Palladium-Catalyzed Cascade Cyclizations . Adv. Synth. Catal. 
2018 , 360 , 3821 –3871 . 10.1002/adsc.201800526 .
Safak C. ; Simsek R. 
Fused 1,4-dihydropyridines as potential calcium modulatory
compounds . Mini-Rev. Med. Chem. 
2006 , 6 , 747 –755 . 10.2174/138955706777698606 .16842124 
Buendia I. ; Tenti G. ; Michalska P. ; Méndez-López I. ; Luengo E. ; Sariani M. ; Padín-Nogueira F. ; López M. G. ; Ramos M. T. ; García A. G. ; Menéndez J. C. ; León R. 
ITH14001, a CGP37157-Nimodipine Hybrid
Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts
Neuroprotection in Cerebral Ischemia . ACS Chem.
Neurosci. 
2017 , 8 , 67 –81 . 10.1021/acschemneuro.6b00181 .27731633 
Mai A. ; Valente S. ; Meade S. ; Carafa V. ; Tardugno M. ; Nebbioso A. ; Galmozzi A. ; Mitro N. ; Fabiani E. D. ; Altucci L. ; Kazantsev A. 
Study of 1,4-Dihydropyridine
Structural
Scaffold: Discovery of Novel Sirtuin Activators and Inhibitors . J. Med. Chem. 
2009 , 52 , 5496 –5504 . 10.1021/jm9008289 .19663498 
Arhancet G.
B. ; Woodard S. S. ; Iyanar K. ; Case B. L. ; Woerndle R. ; Dietz J. D. ; Garland D. J. ; Collins J. T. ; Payne M. A. ; Blinn J. R. ; Pomposiello S. I. ; Hu X. ; Heron M. I. ; Huang H. C. ; Lee L. F. 
Discovery of Novel Cyanodihydropyridines
as Potent Mineralocorticoid Receptor Antagonists . J. Med. Chem. 
2010 , 53 , 5970 –5978 . 10.1021/jm100506y .20672820 
Schade D. ; Lanier M. ; Willems E. ; Okolotowicz K. ; Bushway P. ; Wahlquist C. ; Gilley C. ; Mercola M. ; Cashman J. R. 
Synthesis and SAR
of b-Annulated 1,4-Dihydropyridines
Define Cardiomyogenic Compounds as Novel Inhibitors of TGFβ
Signaling . J. Med. Chem. 
2012 , 55 , 9946 –9957 . 10.1021/jm301144g .23130626 
El
Bakali J. ; Gilleron P. ; Body-Malapel M. ; Mansouri R. ; Muccioli G. G. ; Djouina M. ; Barczyk A. ; Klupsch F. ; Andrzejak V. ; Lipka E. ; Furman C. ; Lambert D. M. ; Chavatte P. ; Desreumaux P. ; Millet R. 
4-Oxo-1,4-dihydropyridines as Selective CB2 Cannabinoid
Receptor Ligands Part 2: Discovery of New Agonists Endowed with Protective
Effect Against Experimental Colitis . J. Med.
Chem. 
2012 , 55 , 8948 –8952 . 10.1021/jm3008568 .23017078 
Budriesi R. ; Ioan P. ; Locatelli A. ; Cosconati S. ; Leoni A. ; Ugenti M. P. ; Andreani A. ; Di Toro R. ; Bedini A. ; Spampinato S. ; Marinelli L. ; Novellino E. ; Chiarini A. 
Imidazo[2,1-b]thiazole
System: A Scaffold Endowing Dihydropyridines with Selective Cardiodepressant
Activity . J. Med. Chem. 
2008 , 51 , 1592 –1600 . 10.1021/jm070681+ .18303827 
Fernández-Morales J.-C. ; Arranz-Tagarro J.-A. ; Calvo-Gallardo E. ; Maroto M. ; Padín J.-F. ; García A. G. 
Stabilizers of Neuronal and Mitochondrial Calcium Cycling
as a Strategy for Developing a Medicine for Alzheimer’s Disease . ACS Chem. Neurosci. 
2012 , 3 , 873 –883 . 10.1021/cn3001069 .23173068 
Marco-Contelles J. ; León R. ; Ríos C. ; Samadi A. ; Bartolini M. ; Andrisano V. ; Huertas O. ; Barril X. ; Javier Luque F. ; Rodríguez-Franco M. I. ; Lόpez B. ; Lόpez M. G. ; García A. G. ; Carreiras M. C. ; Villarroya M. 
Tacripyrines, the First Tacrine-Dihydropyridine
Hybrids, as Multitarget-Directed Ligands for the Treatment of Alzheimer’s
Disease . J. Med. Chem. 
2009 , 52 , 2724 –2732 . 10.1021/jm801292b .19374444 
Bold G. ; Fässler A. ; Capraro H.-G. ; Cozens R. ; Klimkait T. ; Lazdins J. ; Mestan J. ; Poncioni B. ; Rösel J. ; Stover D. ; Tintelnot-Blomley M. ; Acemoglu F. ; Beck W. ; Boss E. ; Eschbach M. ; Hürlimann T. ; Masso E. ; Roussel S. ; Ucci-Stoll K. ; Wyss D. ; Lang M. 
New Aza-Dipeptide Analogues as Potent
and Orally Absorbed HIV-1 Protease Inhibitors: Candidates for Clinical
Development . J. Med. Chem. 
1998 , 41 , 3387 –3401 . 10.1021/jm970873c .9719591 
Basit S. ; Asharf Z. ; Lee K. ; Latif M. 
First macrocyclic 3rd-generation
ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing
strategy update of lorlatinib . Eur. J. Org.
Chem. 
2017 , 134 , 348 –356 . 10.1016/j.ejmech.2017.04.032 .
Schoepfer J. ; Jahnke W. ; Berellini G. ; Buonamici S. ; Cotesta S. ; et al. Discovery of Asciminib
(ABL001), an Allosteric Inhibitor
of the Tyrosine Kinase Activity of BCR-ABL1 . J. Med. Chem. 
2018 , 61 , 8120 –8135 . 10.1021/acs.jmedchem.8b01040 .30137981 
Wei M. ; Peng X. ; Xing L. ; Dai Y. ; Huang R. ; et al. Design, synthesis and biological evaluation
of a series of novel
2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine
derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors . Eur. J. Med. Chem. 
2018 , 154 , 9 –28 . 10.1016/j.ejmech.2018.05.005 .29775937 
Girgis A. S. ; Tala S. R. ; Oliferenko P. V. ; Oliferenko A. A. ; Katritzky A. R. 
Computer-assisted rational design,
synthesis, and bioassay
of non-steroidal anti-inflammatory agents . Eur.
J. Med. Chem. 
2012 , 50 , 1 –8 . 10.1016/j.ejmech.2011.11.034 .22365409 
Liu N. ; Tu J. ; Dong G. ; Wang Y. ; Sheng C. 
Emerging New Targets
for the Treatment of Resistant Fungal Infections . J. Med. Chem. 
2018 , 61 , 5484 –5511 . 10.1021/acs.jmedchem.7b01413 .29294275 
Tardioli S. ; Gooijer C. ; van der
Zwan G. 
Anomalous Photophysics of H1 Antihistamines
in Aqueous Solution . J. Phys. Chem. B 
2009 , 113 , 6949 –6957 . 10.1021/jp9005907 .19388641 
Iwamura R. ; Tanaka M. ; Okanari E. ; Kirihara T. ; Odani-Kawabata N. ; Shams N. ; Yoneda K. 
Identification of a Selective, Non-Prostanoid
EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and
its Prodrug Omidenepag Isopropyl . J. Med. Chem. 
2018 , 61 , 6869 –6891 . 10.1021/acs.jmedchem.8b00808 .29995405 
Li Y. ; Fan W. ; Xu H. W. ; Jiang B. ; Wang S. L. ; Tu S. J. 
A novel
three-component [5 + 1] heterocyclization leading to 2-azafluorenone
synthesis and its polyfunctionalization . Org.
Biomol. Chem. 
2013 , 11 , 2417 –2420 . 10.1039/c3ob40371h .23479067 
Manpadi M. ; Uglinskii P. Y. ; Rastogi S. K. ; Cotter K. M. ; Wong Y. S. C. ; Anderson L. A. ; Ortega A. J. ; Van slambrouck S. ; Steelant W. F. A. ; Rogeli S. ; Tongwa P. ; Antipin M. Y. ; Magedov I. V. ; Kornienko A. 
Three-component
synthesis and anticancer
evaluation of polycyclic indenopyrimidines lead to the discovery of
a novel indenoheterocycles with potent apoptosis inducing properties . Org. Biomol. Chem. 
2007 , 5 , 3865 –3872 . 10.1039/b713820b .18004468 
Padget K. ; Stewart A. ; Charlton P. ; Tilby M. J. ; Austin C. A. 
An investigation
into the formation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
(DACA) and 6-[2-(dimethylamino)ethylamino]-3-hydroxy-7H-indeno[2,1-C]quinolin-7-one dihydrochloride (TAS-103)
stabilised DNA topoisomerase I and II cleavable complexes in human
leukaemia cells . Biochem. Pharmacol. 
2000 , 60 , 817 –821 . 10.1016/s0006-2952(00)00402-0 .10930536 
Tseng C. H. ; Chen Y. L. ; Lu P. J. ; Yang C. N. ; Tzeng C. C. 
Synthesis
and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives . Bioorg. Med. Chem. 
2008 , 16 , 3153 –3162 . 10.1016/j.bmc.2007.12.028 .18180162 
Tseng C. H. ; Tzeng C. C. ; Yang C. L. ; Lu P. J. ; Chen H. L. ; Li H. Y. ; Chuang Y. C. ; Yang C. N. ; Chen Y. L. 
Synthesis
and Antiproliferative Evaluation of Certain Indeno[1,2-c]quinoline Derivatives. Part 2 . J. Med. Chem. 
2010 , 53 , 6164 –6179 . 10.1021/jm1005447 .20662543 
Chen L. ; Conda-Sheridan M. ; Narasimha Reddy P. V. ; Morrell A. ; Park E. J. ; Kondratyuk T. P. ; Pezzuto J. M. ; van Breemen R. B. ; Cushman M. 
Identification, Synthesis, and Biological Evaluation
of the Metabolites of 3-Amino-6-(3′-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6–36),
a Promising Rexinoid Lead Compound for the Development of Cancer Chemotherapeutic
and Chemopreventive Agents . J. Med. Chem. 
2012 , 55 , 5965 –5981 . 10.1021/jm3006806 .22712432 
Evdokimov N. M. ; Van slambrouck S. ; Heffeter P. ; Tu L. ; Le Calvé B. ; Lamoral-Theys D. ; Hooten C. J. ; Uglinskii P. Y. ; Rogelj S. ; Kiss R. ; Steelant W. F. A. ; Berger W. ; Yang J. J. ; Bologa C. G. ; Kornienko A. ; Magedov I. V. 
Structural Simplification of Bioactive Natural Products
with Multicomponent Synthesis. 3. Fused Uracil-Containing Heterocycles
as Novel Topoisomerase-Targeting Agents . J.
Med. Chem. 
2011 , 54 , 2012 –2021 . 10.1021/jm1009428 .21388138 
Feng X. ; Wang J.-J. ; Xun Z. ; Huang Z.-B. ; Shi D.-Q. 
Multicomponent
Strategy to Indeno[2,1-c]pyridine and Hydroisoquinoline
Derivatives through Cleavage of Carbon–Carbon Bond . J. Org. Chem. 
2015 , 80 , 1025 –1033 . 10.1021/jo5025199 .25521750 
Ye F. ; Tran C. ; Jullien L. ; Saux T. L. ; Haddad M. ; Michelet V. ; Ratovelomanana-Vidal V. 
Synthesis
of Fluorescent
Azafluorenones and Derivatives via a Ruthenium-Catalyzed [2 + 2 +
2] Cycloaddition . Org. Lett. 
2018 , 20 , 4950 –4953 . 10.1021/acs.orglett.8b02085 .30070483 
Zi Q.-X. ; Yan S.-J. ; Yang C.-L. ; Li K. ; Lin J. 
Three-Component
Cascade Reaction of 1,1-Enediamines, N,N-Dimethylformamide Dimethyl
Acetal, and 1,3-Dicarbonyl Compounds: Selective Synthesis of Diverse
2-Aminopyridine Derivatives . ACS Omega 
2019 , 4 , 2863 –2873 . 10.1021/acsomega.8b03284 .31459516 
Yu F. ; Yan S. ; Hu L. ; Wang Y. ; Lin J. 
Cascade Reaction
of
Isatins with Heterocyclic Ketene Aminals: Synthesis of Imidazopyrroloquinoline
Derivatives . Org. Lett. 
2011 , 13 , 4782 –4785 . 10.1021/ol201783d .21848302 
Wang B.-Q. ; Zhang C.-H. ; Tian X.-X. ; Lin J. ; Yan S.-J. 
Cascade
Reaction of Isatins with 1,1-Enediamines: Synthesis of Multisubstituted
Quinoline-4-carboxamides . Org. Lett. 
2018 , 20 , 660 –663 . 10.1021/acs.orglett.7b03803 .29323495 
Wang H. ; Li L. ; Lin W. ; Xu P. ; Huang Z. ; Shi D. 
An Efficient
Synthesis of Pyrrolo[2,3,4-kl]acridin-1-one Derivatives
Catalyzed by l-Proline . Org. Lett. 
2012 , 14 , 4598 –4601 . 10.1021/ol302058g .22920713 
Jiang B. ; Wang X. ; Li M.-Y. ; Wu Q. ; Ye Q. ; Xu H.-W. ; Tu S.-J. 
A domino synthetic strategy leading
to two-carbon-tethered fused acridine/indole pairs and fused acridine
derivatives . Org. Biomol. Chem. 
2012 , 10 , 8533 –8538 . 10.1039/c2ob26315g .23011183 
Xu H. ; Zhou B. ; Zhou P. ; Zhou J. ; Shen Y.-H. ; Yu F.-C. ; Lu L.-L. 
Insights into the unexpected chemoselectivity
in Brønsted acid catalyzed cyclization of isatins with enaminones:
convenient synthesis of pyrrolo[3,4-c]quinolin-1-ones
and spirooxindoles . Chem. Commun. 
2016 , 52 , 8002 –8005 . 10.1039/C6CC02659A .
Xu H. ; Zhou P. ; Zhou B. ; Zhou J. ; Shen Y.-H. ; Lu L.-L. ; Yu F.-C. 
Convenient one-step synthesis of
pyrrolo[3,4-c]quinolin-1-ones via TMSCl-catalyzed
cascade reactions of isatins and b-enamino ketones . RSC Adv. 
2016 , 6 , 73760 –73768 . 10.1039/C6RA15492A .
Reviews see: Wang K.-M. ; Yan S.-J. ; Lin J. 
Heterocyclic
Ketene Aminals: Scaffolds for Heterocycle Molecular Diversity . Eur. J. Org. Chem. 
2014 , 1129 –1145 . 10.1002/ejoc.201300929 .
Huang C. ; Yan S.-J. ; Zeng X.-H. ; Dai X.-Y. ; Zhang Y. ; Qing C. ; Lin J. 
Biological
evaluation of polyhalo
1,3-diazaheterocycle fused isoquinolin-1(2H)-imine
derivatives . Eur. J. Med. Chem. 
2011 , 46 , 1172 –1180 . 10.1016/j.ejmech.2011.01.036 .21316818 
Bao H. ; Shao X. ; Zhang Y. ; Deng Y. ; Xu X. ; Liu Z. ; Li Z. 
Specific Synergist
for Neonicotinoid Insecticides:
IPPA08, a cis-Neonicotinoid Compound with a Unique
Oxabridged Substructure . J. Agric. Food Chem. 
2016 , 64 , 5148 –5155 . 10.1021/acs.jafc.6b01512 .27281691 
Chen N. ; Meng X. ; Zhu F. ; Cheng J. ; Shao X. ; Li Z. 
Tetrahydroindeno-[1′,2′:4,5]pyrrolo[1,2-a]imidazol-5(1H)-ones as Novel Neonicotinoid
Insecticides:
Reaction Selectivity and Substituent Effects on the Activity Level . J. Agric. Food Chem. 
2015 , 63 , 1360 –1369 . 10.1021/jf505281p .25611859 
a Yu F.-C. ; Lin X.-R. ; Liu Z. C. ; Zhang J.-H. ; Liu F.-F. ; Wu W. ; Ma Y.-L. ; Qu W.-W. ; Yan S.-J. ; Lin J. 
Beyond the
Antagonism:
Self-Labeled Xanthone Inhibitors as Modeled “Two-in-One”
Drugs in Cancer Therapy . ACS Omega 
2017 , 2 , 873 –889 . 10.1021/acsomega.6b00545 .30023617 
Suryawanshi S. N. ; Pandey S. ; Rashmirathi ; Bhatt B. A. ; Gupta S. 
Chemotherapy
of leishmaniasis
Part VI: Synthesis and bioevaluation of some novel terpenyl S,N- and N,N-acetals . Eur. J. Med. Chem. 
2007 , 42 , 511 –516 . 10.1016/j.ejmech.2006.09.016 .17178176 
Mertens H. ; Troschuetz R. 
Nitroketenaminale,
5. Mitt*: Synthese von N2-substituierten
2-Amino-3-nitropyridinen als Vorstufen von Pyrido[2,3-b]pyrazinen (3-Desazapteridinen) . Arch. Pharm. 
1987 , 320 , 1143 –1149 . 10.1002/ardp.198700023 .
Du X.-X. ; Huang R. ; Yang C.-L. ; Lin J. ; Yan S.-J. 
Synthesis
and evaluation of the antitumor activity of highly functionalised
pyridin-2-ones and pyrimidin-4-ones . RSC Adv. 
2017 , 7 , 40067 –40073 . 10.1039/C7RA06466G .
Li M. ; Shao P. ; Wang S.-W. ; Kong W. ; Wen L.-R. 
Four-Component
Cascade Heteroannulation of Heterocyclic Ketene Aminals: Synthesis
of Functionalized Tetrahydroimidazo[1,2-a]pyridine
Derivatives . J. Org. Chem. 
2012 , 77 , 8956 –8967 . 10.1021/jo3013836 .22970749 
Ma Y.-L. ; Wang K.-M. ; Huang R. ; Lin J. ; Yan S.-J. 
An environmentally
benign double Michael addition reaction of heterocyclic ketene aminals
with quinone monoketals for diastereoselective synthesis of highly
functionalized morphan derivatives in water . Green Chem. 
2017 , 19 , 3574 –3584 . 10.1039/C7GC01435J .
Chen L. ; Huang R. ; Du X.-X. ; Yan S.-J. ; Lin J. 
One-Pot Synthesis
of Highly Functionalized Bicyclic Imidazopyridinium Derivatives in
Ethanol . ACS Sustainable Chem. Eng. 
2017 , 5 , 1899 –1905 . 10.1021/acssuschemeng.6b02622 .
Hu X.-M. ; Zhou B. ; Yang C.-L. ; Lin J. ; Yan S.-J. 
Site-Selective
Reaction of Enaminones and Enamine Esters for the Synthesis of Novel
Diverse Morphan Derivatives . ACS Omega 
2018 , 3 , 5994 –6005 . 10.1021/acsomega.8b00726 .31458790 
Zhang C.-H. ; Huang R. ; Hu X.-M. ; Lin J. ; Yan S.-J. 
Three-Component
Site-Selective Synthesis of Highly Substituted 5H-Chromeno-[4,3-b]pyridines . J. Org. Chem. 
2018 , 83 , 4981 –4989 . 10.1021/acs.joc.8b00099 .29648823

